Sareum Holdings plc
("Sareum" or the "Company")
Appointment of Sole Broker
Cambridge, UK, 30 May 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that Hybridan LLP is now acting as the Company's sole broker with immediate effect.
- END -
For Further Information:
| Sareum Holdings plc Tim Mitchell, CEO | 01223 497700 ir@sareum.co.uk
|
| Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
| 020 7409 3494 |
| Hybridan LLP (Corporate Broker) Claire Noyce
| 020 3764 2341 |
| ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Kumail Waljee | 0203 709 5700 |
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.